ArticleJournal of thoracic disease2019

Randomized phase II trial reporting overall survival advantage by adding local consolidative therapy to systemic therapy for oligometastatic non-small cell lung cancer: another step forward on the long road of evidence-based medicine for oligometastatic disease.

Paul Windisch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.